Comparison · NCT00736255-997448c7
LDX and NRT vs NRT and Placebo: The Number of Subjects in Each Treatment Group Exhibiting Sustained, 4-week Smoking Abstinence, Defined as CO Levels <= 4 Ppm for Each Post-quit Study Visit.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. LDX and NRT vs NRT and Placebo: The Number of Subjects in Each Treatment Group Exhibiting Sustained, 4-week Smoking Abstinence, Defined as CO Levels <= 4 Ppm for Each Post-quit Study Visit. Trial comparisons, record NCT00736255-997448c7. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00736255-997448c7
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.294 | 0.133 | 0.531 | wilson | |
| Risk in group 2 | 0.2 | 0.0705 | 0.452 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0941 | -0.205 | 0.364 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.47 | 0.421 | 5.14 | log | |
| Odds ratio, group 1 over group 2 | 1.67 | 0.323 | 8.59 | log | |
| Number needed to treat, for one more participant with the outcome on LDX and NRT than on NRT and Placebo | 10.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | LDX and NRT | • The first group will receive LDX/SPD489 titrated up to 70 mg qd for 4 weeks after the identified quit date. Subjects will continue to receive NRT 21 mg at week 1 post quit date, then 14mg at week 2 post quit date and 7 at weeks 3 and 4 post quit date.~Lis-dexamphetamine (LDX; Vyvanse) and Transdermal Nicotine Patch: Subjects on this arm will receive Lis-dexamphetamine day after the identified quit date. All subject will start with 30mg once a day and will be titrated up to 50mg then to 70mg over a 3 week period to reach an optimized dose. They will then be maintained on this optimized dose until the 4th week. All subjects will continue to receive transdermal nicotine patch during these weeks. The dose will be tapered down from 21 mg to 14mg after week 1,then to 7 mg after week 2. Subjects will remain at 7mg until the 4th week. | 5 | 17 | OG000 |
| Group 2 | NRT and Placebo | The second group will receive matching placebo and NRT after the quit date.~Placebo and transdermal nicotine patch: Subjects on this arm will receive matching placebo and NRT. | 3 | 15 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- The Number of Subjects in Each Treatment Group Exhibiting Sustained, 4-week Smoking Abstinence, Defined as CO Levels <= 4 Ppm for Each Post-quit Study Visit.
- Description
The primary outcome measure was the proportion of subjects in each treatment group exhibiting sustained, 4-week smoking abstinence, defined as CO levels \<= 4 ppm for each post-quit study visit. Subjects who dropped from the study for any reason were considered to have lapsed.
- Time frame
- 4 weeks
- Population
- Subjects exhibiting sustained 4 week smoking abstinence defined as CO levels \<= 4ppm for each post quit study visit were analyzed for the outcome measure.
Source ClinicalTrials.gov
Trial
- Title
- Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study
- NCT number
- NCT00736255
- Phases
- NA
- Conditions
- Attention Deficit Hyperactivity Disorder, Nicotine Dependence
- Interventions
- Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse), Placebo
- Lead sponsor
- Duke University
- Results first posted
- 2012-09-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00736255?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00736255-997448c7